Relay Therapeutics Inc (NASDAQ: RLAY) kicked off on Friday, up 4.42% from the previous trading day, before settling in for the closing price of $3.39. Over the past 52 weeks, RLAY has traded in a range of $1.77-$10.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -23.05%. While this was happening, its average annual earnings per share was recorded 22.64%. With a float of $130.14 million, this company’s outstanding shares have now reached $171.69 million.
Let’s determine the extent of company efficiency that accounts for 261 employees. In terms of profitability, gross margin is -15.04%, operating margin of -4105.6%, and the pretax margin is -3728.45%.
Relay Therapeutics Inc (RLAY) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Relay Therapeutics Inc is 24.52%, while institutional ownership is 79.03%. The most recent insider transaction that took place on Jul 29 ’25, was worth 57,864. In this transaction an insider of this company sold 15,724 shares at a rate of $3.68, taking the stock ownership to the 377,998 shares. Before that another transaction happened on Jul 28 ’25, when Company’s insider sold 1,359 for $3.74, making the entire transaction worth $5,083. This insider now owns 393,722 shares in total.
Relay Therapeutics Inc (RLAY) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.63 earnings per share (EPS), higher than consensus estimate (set at -0.78) by 0.15. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.38 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 22.64% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.70% during the next five years compared to -23.05% drop over the previous five years of trading.
Relay Therapeutics Inc (NASDAQ: RLAY) Trading Performance Indicators
Take a look at Relay Therapeutics Inc’s (RLAY) current performance indicators. Last quarter, stock had a quick ratio of 20.92. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 73.01.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.95, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.64 in one year’s time.
Technical Analysis of Relay Therapeutics Inc (RLAY)
Looking closely at Relay Therapeutics Inc (NASDAQ: RLAY), its last 5-days average volume was 1.72 million, which is a drop from its year-to-date volume of 2.3 million. As of the previous 9 days, the stock’s Stochastic %D was 59.44%.
During the past 100 days, Relay Therapeutics Inc’s (RLAY) raw stochastic average was set at 80.45%, which indicates a significant increase from 68.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.21 in the past 14 days, which was lower than the 0.23 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.48, while its 200-day Moving Average is $3.81. However, in the short run, Relay Therapeutics Inc’s stock first resistance to watch stands at $3.60. Second resistance stands at $3.66. The third major resistance level sits at $3.76. If the price goes on to break the first support level at $3.44, it is likely to go to the next support level at $3.34. Now, if the price goes above the second support level, the third support stands at $3.28.
Relay Therapeutics Inc (NASDAQ: RLAY) Key Stats
The company with the Market Capitalisation of 610.34 million has total of 172,411K Shares Outstanding. Its annual sales at the moment are 10,010 K in contrast with the sum of -337,710 K annual income. Company’s last quarter sales were recorded 680 K and last quarter income was -70,380 K.
